Vergelijking
Maridebart Cafraglutide vs. Pramlintid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
151126-32-8
Molecuulmassa
geen gegevens
3949.4 g/mol
Halfwaardetijd
geen gegevens
geen gegevens
Sequentie
geen gegevens
geen gegevens
Werkingsmechanisme
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
0
waarvan bij mensen
1
0
Geregistreerde effecten
2
2
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Pramlintid?
- Maridebart Cafraglutide is classified as "Metabool", while Pramlintid is classified as "Metabool". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Pramlintid?
- The highest available evidence level is "Humane RCT" for Maridebart Cafraglutide and "Humane RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Pramlintid in Germany and the United States?
- Duitsland: Maridebart Cafraglutide — Niet goedgekeurd, Pramlintid — Niet goedgekeurd. Verenigde Staten: Maridebart Cafraglutide — Niet goedgekeurd, Pramlintid — Op recept. These are factual summaries with source and review date on the individual pages.